Hypereosinophilic Syndrome (HES)
Conditions
Brief summary
The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.
Detailed description
Retrospective database analysis using TriNetX database to describe HES patient characteristics, journey, and disease burden.
Interventions
OTHERno intervention
not applicable, this is an observational retrospective data analysis study; no interventions in the study
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Diagnosis record of HES (ICD-10-CM D72.11) anytime during 01 October 2020 to 30 June 2023 * At least 12 months of patient insurance record prior to first HES record.
Exclusion criteria
* Any mutation in PDGFRA, PDGFRB or FGFR1 genes (to exclude clonal HES). * History of BCR-ABL tyrosine kinase inhibitor use: imatinib, dasatinib, nolitinib, bosutinib, ponatinib, asciminib (to exclude clonal HES) * History of myeloid leukemia, myeloproliferative disorder, myelodysplastic disorder, myelomonocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukaemia, acute panmyelosis with myelofibrosis, and other specified leukaemias (to exclude reactive HES) * History of helminthiasis or use of anthelmintic medication (to exclude reactive HES) * History of autoimmune disease (to exclude reactive HES) * History of use of specific drugs: antiepileptics, sulfonamides, allopurinol, and immune checkpoint inhibitors (to exclude reactive HES)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of organ systems with HES signs and/or symptoms | 01 October 2020 - the most recent data available in 2023 | To describe the disease burden of HES. |
| Comorbidities prior to first HES record | 01 October 2020- the most recent data available in 2023 | To describe clinical characteristics of patients with HES. |
| Other eosinophilic conditions | 01 October 2020- the most recent data available in 2023 | To describe the clinical characteristics of HES patients. |
| Organ system with HES signs and/or symptoms | 01 October 2020- the most recent data available in 2023 | To describe the disease burden of HES. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Demographic characteristics | 01 October 2020- the most recent data available in 2023 | To describe the demographic characteristics of HES patients and sub-group analysis patients. |
| Patient journey in diagnostic phase | 01 October 2020 - the most recent data available in 2023 | To describe the patient journey in diagnostic phase and in sub-group analysis. |
| HES and non-HES therapies & treatment pattern | 01 October 2020 - the most recent data available in 2023 | To describe the treatment pattern of HES patients and sub-group analysis patients. |
| Clinical outcomes | 01 October 2020 - the most recent data available in 2023 | To describe clinical outcome pre and post index date and compare between biologics and patients treated with anti-IL-5/IL-5Rα therapies. |
Countries
United States
Outcome results
None listed